Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

1.01
-0.0750-6.91%
Pre-market: 1.00-0.0100-0.99%04:00 EDT
Volume:420.70K
Turnover:428.11K
Market Cap:12.91M
PE:-0.62
High:1.16
Open:1.10
Low:0.9700
Close:1.09
52wk High:4.70
52wk Low:0.9700
Shares:12.78M
Float Shares:10.19M
Volume Ratio:1.13
T/O Rate:4.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-4.01
PE(LYR):-0.64

Loading ...

Lantern Pharma Schedules Q2 Operating and Financial Results Webcast

Reuters
·
Aug 07

Lantern Pharma Spins Off Open-Medicine AI Platform

TIPRANKS
·
Aug 04

Lantern Pharma Spins Out Open-Medicine AI Unit to Commercialize Multi-Agent Drug Discovery Platform

Reuters
·
Aug 03

Lantern Pharma (Nasdaq: Ltrn) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

THOMSON REUTERS
·
Aug 03

Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184

TIPRANKS
·
Jul 28

Lantern Pharma Says EMA Clears Phase 1b/2 Lp-184 Bladder Cancer Trial

Reuters
·
Jul 28

Lantern Pharma to Advance Ema-Cleared Phase 1B/2 Trial of Lp-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

THOMSON REUTERS
·
Jul 28

Lantern Pharma Says USPTO Allows Patent Application for Lp-184 Biomarker-guided Solid Tumor Treatment Methods

Reuters
·
Jul 23

Lantern Pharma Publishes Investor Presentation on Ai-driven Oncology Drug Development Platform, Pipeline Programs

Reuters
·
Jul 14

Lantern Pharma launches ZetaOmics computational-biology module

TIPRANKS
·
Jul 08

Lantern Pharma Posts Investor Presentation on Ai-driven Oncology Drug Development Platform and Pipeline

Reuters
·
Jul 02

Lantern Pharma files to sell 2.24M shares of common stock for holders

TIPRANKS
·
Jun 13

Lantern Pharma - Selling Stockholders May Sell up to 2.24 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 13

Lantern Pharma - Lp-300 Plus Chemo Shows No Clinically Meaningful Toxicity Beyond Chemotherapy

THOMSON REUTERS
·
Jun 02

Lantern Pharma - Over 70% of L858r Patients Show Tumor Reduction; 77% Clinical Benefit Rate

THOMSON REUTERS
·
Jun 02

Lantern Pharma - Reports Lp-300 Pfs Benefit Deepens With Treatment Duration in L858r Lung Cancer

THOMSON REUTERS
·
Jun 02

Lantern Pharma - L858r Nsclc Patients Reached 8.9-Month Median Pfs With Lp-300; Durable Responses Beyond Two Years

THOMSON REUTERS
·
Jun 02

Lantern Pharma posts LP-300 Phase 2 HARMONIC trial presentation in EGFR L858R NSCLC

Reuters
·
Jun 02

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress

TIPRANKS
·
Jun 02

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

Reuters
·
May 19